PHARMACEUTICAL IP

  • Our Offering
    • Fractional in-house
    • Start-ups
    • Established pharma
    • International IP counsel
    • Investors
    • Due diligence
  • Fractional in-house
  • Sectors
    • Pharmaceuticals
    • Biotechnology
    • Biologics
    • Cell & gene therapies
    • AI drug discovery
    • Chemistry
  • Insights
    • Articles
    • Webinars
    • Subscribe
  • About us
    • Our team
    • Join us
    • Contact us
  • Our Offering
    • Fractional in-house
    • Start-ups
    • Established pharma
    • International IP counsel
    • Investors
    • Due diligence
  • Fractional in-house
  • Sectors
    • Pharmaceuticals
    • Biotechnology
    • Biologics
    • Cell & gene therapies
    • AI drug discovery
    • Chemistry
  • Insights
    • Articles
    • Webinars
    • Subscribe
  • About us
    • Our team
    • Join us
    • Contact us
  • Our offering
  • Fractional in-house
  • Sectors
  • Insights
  • Our team
  • Join us
  • Our offering
  • Fractional in-house
  • Sectors
  • Insights
  • Our team
  • Join us

Beware of boilerplate: Practical lessons for patent drafting from G1/24 (Claim interpretation)

  • Sector: Uncategorized
  • 11th April 2025
 

Following the high profile hearing last month, we are now waiting for the written decision of the Enlarged Board of Appeal (EBA) in G 1/24. Readers can catch-up on the full background to the case here. There is also still plenty to discuss while we wait. 

G 1/24 relates to the question of how to interpret the claims of a patent, and whether the description of the patent may be used for this purpose. Most patent attorneys like nothing more than arguing about the meaning of words. What then could be better than an argument about how to argue about the meaning of words, as we may liberally paraphrase G 1/24. However, whilst this is all very exciting for patent attorneys, we are still left with the question of the practical implications of G 1/24? Even before the EBA issues its decision, there are some lessons to be learnt from the case on drafting the description of a patent.These lessons are even more important with the increased use of AI patent tools for patent drafting.

Beware of boilerplate

One key lesson from the case at the centre of G 1/24 can be summarised very succinctly. When drafting a patent, beware of overusing boilerplate language. 

The patent at issue in the referring decision to G 1/24 (T 0439/22) was a Philip Morris patent for a heated aerosol-generating article for use with an electrically-operated aerosol-generating device (e.g. a heat-not-burn e-cigarette), in which an “aerosol-forming substrate comprises a gathered sheet of aerosol-forming material” (e.g. a sheet of gathered tobacco). A key question for the novelty of the claim was whether the product disclosed by the prior art disclosed a “gathered” sheet of tobacco. The prior art disclosed a product comprising a tobacco sheet that “may be spirally wound”. The Board of Appeal in the case was convinced that a person skilled in the art would not normally consider the definition of a “gathered tobacco sheet” to include tobacco sheets that were spiralled. The skilled person, it was agreed, would normally understand a gathered tobacco sheet to be one that was “folded and convoluted”. 

However, critically, the description of the patent included the following definition: 

As used herein, the term ‘gathered’ denotes that the sheet of tobacco material is convoluted, folded, or otherwise compressed or constricted substantially transversely to the cylindrical axis of the rod.

For the Board of Appeal in the case, this broader definition of the term “gathered” encompassed the spiralled tobacco sheet disclosed by the prior art. In other words, if the description could be used to redefine terms of the art used in the claims, then the patentee had shot themselves in the foot with their overly broad definition. In the view of the Board of Appeal in the case, using the broadening definition provided by the description, the claimed invention lacked novelty. 

The case in T 0439/22 thus highlights the dangers of unnecessary boilerplate language. Given that the term “gathered” has an accepted definition within the field, why then does the term need to be defined in the description at all? If the patentee is intentionally trying to broaden the scope of protection offered by the claims to include sheets of tobacco not falling under the commonly accepted definition of “gathered”, then the claims would be the best place to do this. The patentee could simply have used different terminology in the claims. The use of the description to redefine words that are used in the claims creates a lack of clarity that is not conducive to legal certainty. As the case in G 1/24 illustrates, this lack of clarity may harm the patentee as well as third parties. 

In short, beyond all the nuanced legal debate, a key practical take-home message from G 1/24 is simply to avoid, as much as possible, unnecessary boilerplate that may undermine your carefully crafted claims. 

The importance of technical field

Arguably, the practical implications of G 1/24 for drafting practice vary according to the technical field. In the mechanical field of patent drafting, the definitions of words can be quite fluid and open to interpretation. It is often difficult in mechanical patents to interpret words without the context of the description. To interpret claim terminology such as for example, housing, member, plate, panel, and flange, it is generally necessary to understand what the purpose of these features are in the invention.

By contrast, in technically specialised fields such as biotech and software, terminology is often more clearly defined in the field. Terms such as cell, DNA, nucleic acid sequence, epitope, and chimeric antigen receptor have well-understood definitions. Of course, there will always be some scope for interpretation, but the definitions of such words are still far more delineated than the words often used in mechanical drafting. It is therefore no surprise that the referring case in G 1/24 was from the mechanical field. The point of contention in G 1/24 relates to a word (“gathered”) that on the face of it appears relatively non-technical and open to interpretation.

However, even within the field of tobacco products, the terminology used in patent claims will of often have well-understood definitions. This was in fact the case in T 0439/22, in which it was accepted that gathered would normally be understood by a skilled person to refer to the type of tobacco sheets manufactured on standard crimping machines and thus not encompass spiralled tobacco. The problem for the patentee was the non-technical definition of gathered provided in the application. Given that “gathered” is a well-understood term in the field, defining it in the specification was arguably unnecessary. 

A practical lesson from G 1/24 is thus to ensure that any definitions of technical terms provided in the specification which differ from their normal technical meaning are included with the full intention of redefining the term. As suggested above, the safest plan would be to define the invention clearly in the claim. 

Beware even more of AI generated boilerplate

The increased use of these tools in the industry also raises interesting questions so far as definitions are concerned. Many of the tools on offer will draft definitions for the description based on your claims. In my experience, without extensive user input and prompting these definitions are often highly unsuitable and are in many cases overly narrowing. Filling the specification with impressive sounding technical language defining terminology used in the claims may give the impression of a well-drafted patent, but this impression would be misleading. G 1/24 is a timely reminder that the description of a patent may be highly influential for how the scope of the claims is determined. AI patent drafting tools to automate a comprehensive glossary of terms based on the claims, should therefore be used with care. 

Final thoughts

Before even the Enlarged Board of Appeal issues its written decision in G 1/24, there are already a number of lessons for patent drafting that can be taken from the issues at stake in the case. Wherever the Enlarged Board of Appeal lands on description-based claim interpretation, the fundamental principle of patent drafting remains the same. If you want the scope of the claims to be clear, the best place to ensure this is in claims. As the arrival of AI drafting tools reminds us, there is no substitute for careful, deliberate drafting of both claims and description.

Related insights...

Referral on description amendments finally confirmed (G1/25 – “Hydroponics”)

  • 29th July 2025
At last, the wait is over. After years of conflicting case law and mounting frustration for practitioners, the Enlarged Board of Appeal is set to rule on the controversial issue of description amendments in G1/25. But will the decision actually bring clarity ?

G 1/24 in the spotlight: Description definitions do not override clear claim language (T 1999/23)

  • 24th July 2025
The latest decision from the EPO to apply the landmark decision in G1/24 on claim interpretation finds that description definitions should not override clear claim lanaguge.

The problem with product-by-process patents (T 1065/23)

  • 18th July 2025
Inventions may be defined in a patent as product, a process, or a product defined by the process that it is made. The choice of patent claim format you choose to define the invention can be highly influential to validity and enforcement later on.

First interpretation of G 1/24 (the description must always be consulted) (T 1561/23)

  • 14th July 2025
Did G1/24 really change everything about claim interpretation, or does it simply formalize what Boards of Appeal were already doing case-by-case?”

Pitfalls of cell therapy manufacturing IP – A case study (T 0868/23)

  • 8th July 2025
In cell therapy the industry mantra is that the product is the process. However, this case illustrates that the best patent protection for a cell therapy is derived from the product. 

Non-reproducible commercial products are prior art (G1/23)

  • 7th July 2025
Is your product prior art if you disclose it before you file your patent, but without disclosing how it is made or what it is made from? The EBA answers “yes”.

The morality (and patentability) of inventions derived by immoral means (T 2510/18)

  • 25th June 2025
Should patents be granted for inventions born from unethical practices, even if they offer significant societal benefits?

How to read a biotech patent

  • 23rd June 2025
Learn how to quickly search for and extract key information from biotech patent documents.

EBA decides G1/24 on claim interpretation: The description should always be consulted

  • 19th June 2025
Understanding how patent claims are interpreted is crucial, and a recent EPO decision, G 1/24, provides new guidance: always consult the patent’s full description and drawings, not just the claims themselves.

Is it time for patent offices to enter the bioinformatic age?

  • 13th June 2025
In a world in which incalculable amounts of sophisticated sequence data is freely available, are the clunky processes necessary to input patent sequence data really fit-for-purpose?
All Insights

evolve® is a trading entity of Evolve Intellectual Property Limited. Evolve Intellectual Property Limited is regulated by the Intellectual Property Regulation Board (IPReg). Details of the UK professional rules can be found on the IPReg website

registered address: 49 Greek Street, London, England, W1D 4EG

website out of house

© 2025 All Rights Reserved

Keep in touch

Subscribe

Contact Us